Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

被引：0
|
作者：
Thitima Kongnakorn
Tereza Lanitis
Lieven Annemans
Vincent Thijs
Sophie Marbaix
机构：
[1] Evidera,Laboratory of Neurobiology
[2] Evidera,Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND)
[3] Ghent University (Ugent),Department of Neurology
[4] Brussels University (VUB),undefined
[5] Vesalius Research Center,undefined
[6] VIB,undefined
[7] University of Leuven (KU Leuven),undefined
[8] University Hospital Leuven,undefined
[9] Pfizer,undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：753 / 753
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING
    Hori, M.
    Tanahashi, N.
    Akiyama, S.
    Kiyabu, G.
    Dorey, J.
    Goto, R.
    VALUE IN HEALTH, 2019, 22 : S554 - S555
  • [42] Optimising stroke prevention in non-valvular atrial fibrillation
    Ederhy, Stephane
    Cohen, Ariel
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (15) : 2079 - 2094
  • [43] RIVAROXABAN IN PREVENTION OF STROKE IN ELDERLY PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Yavelov, I. S.
    KARDIOLOGIYA, 2019, 59 (12) : 4 - 11
  • [44] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Nissan, Ran
    Spectre, Galia
    Hershkovitz, Avital
    Green, Hefziba
    Shimony, Shai
    Cooper, Lisa
    Nakav, Sigal
    Shochat, Tzippy
    Grossman, Alon
    Fuchs, Shmuel
    DRUGS & AGING, 2019, 36 (02) : 165 - 177
  • [45] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Ran Nissan
    Galia Spectre
    Avital Hershkovitz
    Hefziba Green
    Shai Shimony
    Lisa Cooper
    Sigal Nakav
    Tzippy Shochat
    Alon Grossman
    Shmuel Fuchs
    Drugs & Aging, 2019, 36 : 165 - 177
  • [46] New Anticoagulants for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
    Hoecht, T.
    Frick, M.
    Alber, H.
    Huber, K.
    JOURNAL FUR KARDIOLOGIE, 2012, 19 (3-4): : 55 - 62
  • [47] Apixaban Failure in Prevention of Ischemic Cerebrovascular Accidents in Non-valvular Atrial Fibrillation Patients
    Zmaili, Mohammad
    Alzubi, Jafar
    Gad, Mohamed
    Abu-Haniyeh, Ahmed
    Saliba, Walid I.
    Wazni, Oussama M.
    Hussein, Ayman
    CIRCULATION, 2020, 142
  • [48] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [49] A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Ryazhenov, V. V.
    Gorokhova, S. G.
    Gorokhov, V
    VALUE IN HEALTH, 2018, 21 : S99 - S99
  • [50] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Oyaguez, Itziar
    Suarez, Carmen
    Luis Lopez-Sendon, Jose
    Ramon Gonzalez-Juanatey, Jose
    de Andres-Nogales, Fernando
    Suarez, Jorge
    Polanco, Carlos
    Soto, Javier
    PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 485 - 497
12345